ViiV Healthcare has completed its acquisition of Bristol-Myers Squibb’s portfolio of HIV research and development assets, having secured antitrust clearance from authorities in the US.

The move gives ViiV, which is majority owned by GSK, with Pfizer and Shionogi as shareholders, “one of the most robust HIV pipelines in the industry,” noted chief executive Dominique Limet.

“The assets that we have acquired complement our existing portfolio and could lead to new medicines and combinations addressing a broad range of treatment and prevention needs of people living with HIV.”